Read our COVID-19 research and news.

Webinar Technology

Multiplexed immunohistochemistry: Illuminating the tumor microenvironment to study cancer-immune mechanisms

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Multiplexed immunohistochemistry: Illuminating the tumor microenvironment to study cancer-immune mechanisms

Recorded 02 November 2016


As immuno-oncology takes center stage in the battle against cancer, the need for biomarkers has become even more acute, with response rates continuing in the 20%–30% range and the menu of options, including combination therapies, growing at an accelerating pace. The specific immunoarchitecture characteristics of the microenvironment in which a particular tumor grows may be both prognostic and predictive of response to these new immunotherapies. Multiplex immunofluorescence is the most effective, efficient way to identify specific immune cell types, their location, and their state of activation, as well as the presence of immunoactive molecular expression, all at the same time. This method is highly beneficial for exploring immune evasion mechanisms and finding potential biomarkers that allow researchers to assess the mechanism of action and predict and track response. This live, online seminar will take the viewer through validation of this multiplexing technique, including a comparison with singleplex immunofluorescence and standard (chromogenic) immunohistochemistry, as well as an assessment of intersite reproducibility and the influence of staining order on quantitation.

During the webinar, the viewers will:

  • Gain a clearer understanding of multiplex immunofluorescence and how it compares with singleplex and current immunohistochemical techniques
  • See experimental evidence of the real-world application of multiplexing and how it can be applied to study the tumor microenvironment.

The webinar will last approximately 60 minutes.

To learn more about products or technologies related to this webinar, go to:

Speaker bios

Janis Taube, M.D., M.Sc.

Johns Hopkins Hospital
Baltimore, MD

Dr. Taube is the director of the Dermatopathology Division and Fellowship at Johns Hopkins University School of Medicine. Her research interests center on immune evasion by solid tumors—specifically studying the PD-L1/PD-1 axis—and the identification of potential biomarkers of response to novel immunotherapies. This inquiry requires a focus on immunohistochemical and molecular methods for identifying cell-surface antigens and signaling pathways in paraffin-embedded tissue. Dr. Taube’s laboratory described PD-L1–mediated adaptive immune resistance by melanoma, a finding that has now been extended to other tumor types. She also developed a robust immunohistochemistry assay and interpretation methods for studying PD-L1 as it relates to therapeutic response. Versions of this assay are now approved by the U.S. Food and Drug Administration for clinical use. Her ongoing research efforts are aimed at further characterizing the local tumor microenvironment, with the goal of developing rational treatment combinations and improving patient selection algorithms.

Clifford Hoyt

PerkinElmer, Inc.
Hopkinton, MA

Mr. Hoyt is a technology strategist in the area of oncology, helping to identify clinical opportunities that can be addressed through new technologies and capabilities. This includes forming collaborations and partnerships with academic and industrial institutions, and managing an applications group on the PerkinElmer, Inc. Hopkinton site to develop methods for analyzing clinical pathology samples. Mr. Hoyt joined PerkinElmer, Inc. through the acquisition of CRI, Inc., of which he was a founder. Over the course of his career, he has been principle investigator on a number of NIH research grants, and played a key role in the development and commercialization of several innovative technologies and products, including metrology instruments, laser controllers, telecommunications components, optical components, imaging systems for in vitro fertilization, and in vivo and pathology imaging systems, which is his main focus today. Mr. Hoyt received a B.A. in physics from Williams College in 1983 and Master’s in mechanical engineering from the Massachusetts Institute of Technology in 1987. He is a named inventor on over 20 patents.

Sean Sanders, Ph.D.

Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently, Dr. Sanders is the Director and Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here